The company will operate independently but will leverage Gamma’s other operating companies, Astrea Bioseparations and Univercells Technologies
Gamma Biosciences has agreed to acquire BioMagnetic Solutions (BMS).
BMS has developed immunomagnetic cell separation systems using nanoscale ferrofluids for highly specific cell selection and other bioseparation applications. The ferrofluids reportedly provide high surface area selectivity without the need for columns and expensive consumable sets. The ferrofluid based affinity sorting reagents can be integrated into single-use magnetic separation platforms (X-GRAFFE) at research, clinical, and commercial scale.
“We are excited to enter the next phase of the BioMagnetic Solutions journey and continue our progress in supporting efficient selection and manipulation of specific subsets of therapeutically valuable cells using our next-generation ferrofluid affinity reagents,” said Paul Liberti, CEO and Chief Scientific Officer of BioMagnetic Solutions. “With existing GLP grade reagents being developed to integrate into a robust cGMP platform, we believe this technology will be able to ultimately support rapid development efforts for new cell and gene-based medicines at scale.”
“We are thrilled to welcome Paul and the BMS team to Gamma. This acquisition highlights our focus on investing in innovation-driven companies with the potential to enable the next generation of manufacturing for advanced therapies,” said Matt Gunnison, President of Gamma Biosciences. “As part of Gamma Biosciences, BMS will have access to the support and resources required to further develop and commercialise X-GRAFFE and the full range of its cGMP immunomagnetic separation offering,” added Gunnison.